|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Hughes, PhD, says ultimately, the goal of OOC technology is to improve the translatability of data between the lab and the clinic. Through a lung-on-a-chip approach, it is possible to recreate the histoarchitecture, phenotype, and function of bronchial and alveolar areas of the lung.
|
|
|
Julie Suman, PhD, Sebastien Cordier, and Estelle Verger discuss the properties of the ETFE film coating technology used for PremiumCoat(R) vial stoppers and pre-filled syringe plungers. When combined with pure Bromobutyl formulation, the film forms a barrier that can reduce the number of leachables transferred into the solution, and their quantity by up to 98%.
|
|
|
Nancy Lurker, President and CEO of EyePoint Pharmaceuticals, discusses how she is not only working to disrupt treatment paradigms in ophthalmic drug delivery, but also disrupting leadership paradigms as a female CEO of a company with 2020 total revenues of $34.4 million.
|
|
|
Ian Jenkins, Director of Science, and Jeff Moses, CMO at GATC Health, discuss the combined benefits of their MAT platform and Liquid Biosciences’ Emerge mathematical evolution platform to help identify the right biology sooner and focus on a smaller set of potential compounds early in the pre-clinical development process to enable pharma companies to develop drugs with more efficiency and a higher success rate.
|
|
|
|
|
|
|
|
|

BIOVECTRA is a global biotech and pharmaceutical CDMO that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients. Flexibility, creativity, process optimization and compliance are at the heart of our method. With more than 50 years of experience, 550+ employees, and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes. Click here for more.
|
|
|
|
|
|
 |
|
Hillstream BioPharma Inc. recently announced the FDA granted Orphan Drug Designation to HSB-1216 for Uveal Melanoma (UM). Hillstream continues to….
|
|
 |
|
Adial Pharmaceuticals, Inc. recently announced the closing of its previously announced registered direct offering, whereby a single accredited institutional investor purchased approximately….
|
|
 |
|
Skye Bioscience, Inc. recently announced it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100 ophthalmic nanoemulsion in support of the company’s….
|
|
 |
|
Zealand Pharma A/S recently announced completion of patient enrollment in the second Phase 3-trial, 17103, of dasiglucagon for the treatment of Congenital hyperinsulinism (CHI) in….
|
|
 |
|
Cerevel Therapeutics recently announced positive results from its Phase 1 healthy volunteer clinical trial to evaluate darigabat, a novel alpha-2/3/5 selective GABAA receptor positive allosteric modulator….
|
|
|
|
|
Upcoming eNewsletter Features:
March 2 – Transdermal/Topical Delivery
March 9 – Particle Design Technology
|
|
|
|
|
|
|
|